Vericel (VCEL) Reaches $13.10 After 7.00% Up Move; MIDGARD PROSJEKT I ASA ORDINARY SHARES (MDRDF) Sellers Increased By 4.31% Their Shorts

June 8, 2018 - By Linda Rogers


MIDGARD PROSJEKT I ASA ORDINARY SHARES (OTCMKTS:MDRDF) had an increase of 4.31% in short interest. MDRDF’s SI was 176,500 shares in June as released by FINRA. Its up 4.31% from 169,200 shares previously. It closed at $10.3833 lastly. It is down 0.00% since June 8, 2017 and is . It has underperformed by 12.57% the S&P500.

The stock of Vericel Corporation (NASDAQ:VCEL) is a huge mover today! The stock increased 3.56% or $0.45 during the last trading session, reaching $13.1. About 403,049 shares traded. Vericel Corporation (NASDAQ:VCEL) has risen 389.29% since June 8, 2017 and is uptrending. It has outperformed by 376.72% the S&P500. Some Historical VCEL News: ; 20/04/2018 – DJ Vericel Corporation, Inst Holders, 1Q 2018 (VCEL); 11/05/2018 – PNC Financial Services Group Buys New 1.7% Position in Vericel; 30/05/2018 – Vericel Corp Announces Proposed Public Offering of Common Stk; 14/05/2018 – Next Century Growth Investors Buys New 1% Position in Vericel; 05/04/2018 – Vericel Investor Day Scheduled By Trout Group for Apr. 11; 12/03/2018 Vericel to Host Analyst and Investor Day on April 11, 2018; 23/03/2018 – Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years; 08/05/2018 – Vericel 1Q Loss/Shr 21c; 17/05/2018 – Vericel 31.3% Owned by Hedge FundsThe move comes after 9 months positive chart setup for the $546.03 million company. It was reported on Jun, 8 by We have $14.02 PT which if reached, will make NASDAQ:VCEL worth $38.22M more.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $546.03 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

More notable recent Vericel Corporation (NASDAQ:VCEL) news were published by: which released: “Vericel Corporation Announces Proposed Public Offering of Common Stock” on May 30, 2018, also with their article: “Vericel (VCEL) Prices 5M Share Common Offering at $13/Sh” published on June 01, 2018, published: “Vericel Q1 Results: Full Speed Ahead” on May 27, 2018. More interesting news about Vericel Corporation (NASDAQ:VCEL) were released by: and their article: “Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option …” published on June 05, 2018 as well as‘s news article titled: “Vericel to Present at the Jefferies 2018 Global Healthcare Conference” with publication date: May 25, 2018.

Analysts await Vericel Corporation (NASDAQ:VCEL) to report earnings on August, 8. They expect $-0.10 EPS, down 25.00% or $0.02 from last year’s $-0.08 per share. After $-0.15 actual EPS reported by Vericel Corporation for the previous quarter, Wall Street now forecasts -33.33% EPS growth.

Among 5 analysts covering Vericel (NASDAQ:VCEL), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Vericel had 15 analyst reports since March 11, 2016 according to SRatingsIntel. The company was maintained on Tuesday, January 2 by Piper Jaffray. The firm has “Buy” rating by BTIG Research given on Wednesday, August 9. Leerink Swann initiated Vericel Corporation (NASDAQ:VCEL) on Wednesday, April 4 with “Buy” rating. The firm earned “Buy” rating on Tuesday, October 3 by Piper Jaffray. The rating was maintained by BTIG Research with “Buy” on Tuesday, November 7. The stock of Vericel Corporation (NASDAQ:VCEL) earned “Overweight” rating by Piper Jaffray on Thursday, December 22. The rating was maintained by BTIG Research on Thursday, April 12 with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, August 9 report. Bank of America downgraded Vericel Corporation (NASDAQ:VCEL) on Tuesday, April 5 to “Neutral” rating. As per Friday, March 11, the company rating was upgraded by Needham.

Vericel Corporation (NASDAQ:VCEL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts